Zevra Q2 2026 net revenue $39.7M, up 53% YoY; MIPLYFFA drives growth

ZEVRA THERAPEUTICS, INC.

Net revenue $39.7M, including $30.2M from MIPLYFFA; up from $25.9M in Q2 2025.
Net income $8.8M ($0.14 per share); adjusted net income $15.2M ($0.25 per share).
Cash, cash equivalents and investments $260.2M as of June 30, 2026.
14 MIPLYFFA prescription enrollment forms in Q2; total 184 since launch; 69% covered lives.
66 patients enrolled in Phase 3 DiSCOVER trial for celiprolol; EU MAA re-examination requested.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.